A dynamic evaluation system for the therapeutic effect of chronic obstructive pulmonary disease

Abstract

This invention relates to the field of drug efficacy evaluation technology, specifically to a dynamic evaluation system for the efficacy of chronic obstructive pulmonary disease (COPD). The invention first acquires efficacy parameters for each medical examination indicator during each efficacy evaluation period since the patient began medication. Further, it determines the reference time period for the current moment based on the single medication dosage. Based on monitoring data within all reference time periods for each duration, it determines the future follow-up appointment time and evaluates the efficacy. This invention compares two types of data obtained from daily monitoring and medical examinations, and combines them with the patient's medication history to accurately evaluate efficacy. Then, based on efficacy evaluation periods with similar medication dosages in the long-term management of COPD, it evaluates the efficacy under each duration (i.e., the follow-up interval) to determine the optimal future follow-up appointment time, i.e., the optimal management period for the current stage. This allows patients to have reasonable follow-up appointments, assisting doctors in dynamically adjusting medication regimens, thereby improving the dynamic evaluation effect of patient efficacy.

Description

Technical Field

[0001] This invention relates to the field of drug efficacy evaluation technology, specifically to a dynamic evaluation system for the efficacy of chronic obstructive pulmonary disease. Background Technology

[0002] Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease that typically manifests as shortness of breath that gradually worsens, severely impacting patients' quality of life. Patients usually need to take medication continuously to control symptoms and slow disease progression, while also requiring frequent follow-up visits to dynamically assess the efficacy of medication at different stages and adjust the medication regimen in a timely manner.

[0003] Currently, regular follow-up visits are commonly used to dynamically assess the efficacy of medication at each stage. However, regular follow-up visits have certain limitations. Too short an interval between visits may be a waste of medical resources, while too long an interval will make it difficult for relevant medical staff to adjust medication decisions in a timely manner, thus leading to poor dynamic assessment of the efficacy of chronic obstructive pulmonary disease. Summary of the Invention

[0004] To address the technical problem of poor dynamic evaluation of treatment efficacy for chronic obstructive pulmonary disease (COPD), the present invention aims to provide a dynamic evaluation system for COPD treatment efficacy, the specific technical solution of which is as follows:

[0005] A dynamic evaluation system for the treatment efficacy of chronic obstructive pulmonary disease, the system comprising:

[0006] Data acquisition module: used to acquire the number of times the patient did not take medication, the single dose, the parameter curve of each daily self-test indicator, and the change in each medical examination indicator during each efficacy evaluation period since the patient started taking medication; among which the medical examination indicators include the daily self-test indicators;

[0007] Data analysis module: used to obtain efficacy parameters for each medical examination indicator based on the changing trend of the parameter curve of each daily self-test indicator and the change in the indicator of each medical examination indicator during each efficacy evaluation period, combined with the number of times medication was not used and the single dose of medication.

[0008] The efficacy assessment module is used to determine the reference time period for the current moment from all efficacy assessment time periods based on the similarity characteristics of the single dose; and to determine the future follow-up time for the current moment based on the fluctuation characteristics of the efficacy parameters under all medical examination indicators and the parameter curves of all daily self-test indicators within all reference time periods for each duration, and to assess the efficacy at the future follow-up time.

[0009] Furthermore, the efficacy evaluation period is the time period between adjacent visits.

[0010] Furthermore, the method for obtaining the therapeutic parameters includes:

[0011] The daily self-test indicators in the medical examination and testing indicators are used as target indicators, and the efficacy confidence weights of the other medical examination and testing indicators are set to a constant of 1. During each efficacy evaluation period, the efficacy confidence weights of each target indicator are obtained based on the change of each target indicator and the difference between adjacent parameters in the parameter curve, combined with the number of times medication was not used.

[0012] During each efficacy evaluation period, based on the single dose and the change in each medical examination indicator, the initial efficacy parameters for each medical examination indicator are obtained. The initial efficacy parameters are then weighted using the efficacy confidence weights for each medical examination indicator, and the weighted results are used as the efficacy parameters.

[0013] Furthermore, the method for obtaining the efficacy confidence weight of the target indicator includes:

[0014] The influence weight of medication use is obtained based on the number of times medication was not used during each efficacy evaluation period;

[0015] During each efficacy evaluation period, for each target indicator, the self-tested improvement change is obtained based on the difference between adjacent parameters in the parameter curve. The self-tested improvement change is then weighted using the medication influence weight to obtain the self-tested improvement parameter.

[0016] During each efficacy evaluation period, the improvement parameters are obtained based on the change in each medical visit test indicator, and the efficacy confidence weight is obtained based on the difference between the improvement parameters of each target indicator and the self-tested improvement parameters.

[0017] Furthermore, the method for obtaining the weight of the medication effect includes:

[0018] The ratio of the number of times no medication was used to the number of times medication was used was negatively correlated and normalized, and the normalized value was used as the weight of the impact of medication.

[0019] Furthermore, the method for obtaining the initial therapeutic parameters includes:

[0020] The negative correlation normalized value of the single dose within each efficacy evaluation period is used as the medication sensitivity weight. Under each medical examination indicator, the medication sensitivity weight is used to weight the corresponding medical improvement parameter, and the weighted result is used as the initial efficacy parameter.

[0021] Furthermore, the method for obtaining the reference time period includes:

[0022] The patient's single dose at the current moment is taken as the current dose. The single dose and the current dose in each efficacy evaluation period are clustered. All efficacy evaluation periods corresponding to all single doses other than the current dose in the cluster containing the current dose are taken as the reference period for the current moment.

[0023] Furthermore, the method for obtaining the future follow-up visit time includes:

[0024] Within each reference period, the attention weight of each target indicator is obtained based on the fluctuation characteristics of the parameter curve of each target indicator, and the attention weight of the other medical examination and testing indicators other than the target indicators is set as a preset positive parameter.

[0025] All the reference time periods are classified according to their duration. In each category corresponding to each duration, the expected efficacy value for each duration is obtained based on the attention weight of all medical examination indicators and the efficacy parameters within all reference time periods.

[0026] The duration corresponding to the maximum value of the expected therapeutic effect is taken as the expected therapeutic effect assessment duration at the current moment, and the future follow-up visit time is determined using the expected therapeutic effect assessment duration and the current moment.

[0027] Furthermore, the method for obtaining the attention weight of the target indicator includes:

[0028] The normalized value of the variance of the parameter curve for each target indicator is used as the attention weight for each target indicator.

[0029] Furthermore, the method for obtaining the expected therapeutic effect value includes:

[0030] Under each type of duration, the corresponding efficacy parameter is weighted using the attention weight of each medical examination and testing indicator within each reference time period, and the weighted summation result corresponding to all reference time periods is used as the expected efficacy sub-parameter under each medical examination and testing indicator.

[0031] The sum of the expected efficacy sub-parameters for all medical examination indicators under each duration is taken as the expected efficacy value for each duration.

[0032] The present invention has the following beneficial effects:

[0033] This invention first acquires monitoring data such as the number of times medication was not used, the single dose, the parameter curves of each daily self-test indicator, and the change in each medical examination indicator during each efficacy evaluation period since the patient began self-medication. Then, within each efficacy evaluation period, the changing trends of the parameter curves of each daily self-test indicator and the change in each medical examination indicator are used to provide a control basis, thereby helping to assess the confidence of the monitoring data. Furthermore, the impact of medication behavior and medication sensitivity are assessed by combining the number of times medication was not used and the single dose, so as to accurately obtain the efficacy parameters under each medical examination indicator. Further, the efficacy evaluation periods with similar medication dosages in long-term management are used as a reference to determine the reference period at the current moment. Then, based on the fluctuation characteristics of the efficacy parameters under all medical examination indicators and the parameter curves of all daily self-test indicators in all reference periods under each duration, the future follow-up time is determined at the current moment, and the efficacy is evaluated at the future follow-up time. This invention compares two types of data obtained from daily monitoring and medical examinations, and combines them with the patient's medication to accurately assess efficacy. Then, based on the efficacy assessment period of similar medication dosage in the long-term management of chronic obstructive pulmonary disease, it evaluates the efficacy under each time interval, i.e., the follow-up visit interval, to determine the optimal time for future follow-up visits, i.e., to determine the optimal management period for the current stage. This allows patients to have reasonable follow-up visits to assist doctors in dynamically adjusting medication plans, thereby improving the dynamic assessment effect of patient efficacy. Attached Figure Description

[0034] To more clearly illustrate the technical solutions and advantages in the embodiments of the present invention or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0035] Figure 1 A system block diagram of a dynamic evaluation system for the treatment efficacy of chronic obstructive pulmonary disease provided in one embodiment of the present invention;

[0036] Figure 2 A flowchart illustrating a method for obtaining therapeutic parameters according to an embodiment of the present invention;

[0037] Figure 3 This is a flowchart illustrating a method for obtaining future follow-up appointment times according to an embodiment of the present invention. Detailed Implementation

[0038] To further illustrate the technical means and effects adopted by the present invention to achieve its intended purpose, the following, in conjunction with the accompanying drawings and preferred embodiments, details the specific implementation, structure, features, and effects of a dynamic evaluation system for the treatment efficacy of chronic obstructive pulmonary disease (COPD) proposed according to the present invention. In the following description, different "one embodiment" or "another embodiment" do not necessarily refer to the same embodiment. Furthermore, specific features, structures, or characteristics in one or more embodiments can be combined in any suitable form.

[0039] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.

[0040] The following description, in conjunction with the accompanying drawings, details the specific scheme of the dynamic evaluation system for the treatment efficacy of chronic obstructive pulmonary disease provided by this invention.

[0041] Please see Figure 1 The diagram shows a system block diagram of a dynamic evaluation system for the efficacy of chronic obstructive pulmonary disease provided by an embodiment of the present invention. The system includes a data acquisition module 101, a data analysis module 102, and an efficacy evaluation module 103.

[0042] It should be noted that the embodiments of the present invention are aimed at the dynamic evaluation of the efficacy of chronic obstructive pulmonary disease (COPD) patients during long-term follow-up treatment, that is, each COPD patient has a historical medication treatment record to provide a basis for subsequent analysis.

[0043] Data acquisition module 101: used to acquire the number of times the patient did not take medication, the amount of medication taken at one time, the parameter curve of each daily self-test indicator, and the change in each medical examination indicator during each efficacy evaluation period since the patient started taking medication; among which the medical examination indicators include the daily self-test indicators.

[0044] It should be noted that the dynamic evaluation method for the efficacy of treatment is the same for each patient with chronic obstructive pulmonary disease. Here, we will only use any one patient as an example for analysis and description.

[0045] In one embodiment of the present invention, starting from the time a patient with chronic obstructive pulmonary disease begins taking medication, a portable measuring device such as a smartwatch is provided to collect parameter curves of each daily self-test indicator in real time during each efficacy evaluation period; wherein, the daily self-test indicators include at least indicators reflecting respiratory function or lung function such as heart rate, blood oxygen saturation and respiratory rate.

[0046] In a preferred embodiment of the present invention, all medical visits of the patient since the start of medication are recorded simultaneously, including follow-up visits and emergency visits, and the time of each visit is the end time of the patient's visit. After the visit, the doctor may adjust the patient's medication regimen based on the visit situation, so the time period between adjacent visits is taken as a efficacy evaluation period. It should be noted that the medication regimen, such as the set single dose and frequency of medication, may be different in different efficacy evaluation periods.

[0047] In one embodiment of the present invention, the smartwatch will also set the single dose and all medication times according to the medication plan in each efficacy evaluation period, automatically remind the patient to take the medication on schedule, and record whether the patient has taken the medication, thereby obtaining the number of times the patient has not taken the medication and the single dose in each efficacy evaluation period.

[0048] Considering that the relevant vital sign data collected by the smart bracelet may have some errors, one embodiment of the present invention will use professional hospital instruments to conduct further relevant tests on the patient at each visit, and obtain the change in each test indicator to provide further data reference for subsequent evaluation of efficacy;

[0049] The medical examination indicators include daily self-test indicators, including at least heart rate, blood oxygen saturation, respiratory rate, FEV1 / FVC ratio, airway resistance, peak expiratory flow (PEF), and 6-minute walk test (6MWT). For each medical examination indicator, the indicator value at the end of each efficacy evaluation period is subtracted from the indicator value at the beginning of the period to obtain the indicator change.

[0050] It should be noted that after acquiring the above data using a smartwatch and professional hospital instruments, the data acquisition module is connected to the smartwatch and hospital information system through a set protocol such as MQTT or WebSocket to receive and transmit the data to the data analysis module for analysis. This is existing technology and will not be elaborated further.

[0051] Data Analysis Module 102: Used to obtain efficacy parameters for each daily self-test indicator based on the changing trend of the parameter curve of each daily self-test indicator and the change in the indicator of each outpatient test indicator, combined with the number of times medication was not used and the dosage of medication per session, during each efficacy evaluation period.

[0052] Considering that during each efficacy evaluation period, patients will experience improved lung or respiratory function after taking medication regularly and in the prescribed dosage according to the doctor's prescription, and both daily self-test indicators and medical examination indicators will improve, with lower dosages resulting in greater improvement and better efficacy; while if patients do not take medication on time during the efficacy evaluation period, the efficacy may be poor; and considering the changing trends of the parameter curves for each daily self-test indicator and the changes in each medical examination indicator, these can be used to assess whether the patient's lung or respiratory function has improved.

[0053] Based on this, in each efficacy evaluation period, the embodiments of the present invention will obtain efficacy parameters for each daily self-test indicator based on the changing trend of the parameter curve of each daily self-test indicator and the change in the indicator of each medical examination indicator, combined with the number of times medication was not used and the dosage of a single medication. The efficacy parameters reflect the improvement of the patient's condition under the medication regimen in each efficacy evaluation period, and prepare for determining the appropriate follow-up time at the current moment by combining the patient's efficacy in all efficacy evaluation periods under similar medication regimens. This will help relevant medical staff adjust medication decisions in a timely manner and improve the dynamic evaluation effect of the efficacy of chronic obstructive pulmonary disease.

[0054] Preferably, in one embodiment of the present invention, the method for obtaining therapeutic parameters includes:

[0055] Please see Figure 2 The diagram illustrates a flowchart of a method for obtaining therapeutic parameters according to an embodiment of the present invention, specifically including:

[0056] Step S201: Take the daily self-test indicators in the medical examination and testing indicators as the target indicators, and set the efficacy confidence weight of the other medical examination and testing indicators other than the target indicators to a constant of 1; within each efficacy evaluation period, obtain the efficacy confidence weight of each target indicator based on the change of each target indicator and the difference between adjacent parameters in the parameter curve, combined with the number of times no medication was used.

[0057] Considering that the daily self-test indicators are collected by smart bracelets, the collected parameter curves may have certain errors due to the patient's wearing habits, resulting in relatively low confidence. At the same time, missed or interrupted medication by the patient may have a certain impact on the recovery of lung or respiratory function, thus affecting the accurate assessment of efficacy.

[0058] Furthermore, considering that the indicators for medical examination include daily self-testing indicators, if the changes in vital signs reflected by a certain indicator during daily self-testing and medical examination are similar, it can be said that the parameter curve or indicator parameter under that indicator can be used to accurately assess the efficacy. Moreover, the changes in the indicators under the medical examination are collected by medical professionals through medical instruments under the professional operation of medical staff, and the confidence level is relatively high.

[0059] Based on this, in one embodiment of the present invention, the daily self-test indicators in the medical examination and testing indicators are first used as target indicators. During each efficacy evaluation period, based on the change in each target indicator and the difference between adjacent parameters in the parameter curve, the similarity of the changes in vital signs reflected by the target indicators in the daily self-test and medical examination and testing processes is evaluated. Furthermore, the impact of the number of times medication was not used is combined to evaluate the degree of its influence on efficacy, so as to obtain the efficacy confidence weight of each target indicator. Since the efficacy confidence weight of each target indicator is normalized in the subsequent process, the efficacy confidence weight of the remaining medical examination and testing indicators other than the target indicators is set to a constant 1.

[0060] In a preferred embodiment of the present invention, the method for obtaining the efficacy confidence weight of the target indicator includes:

[0061] The influence weight of medication use is obtained based on the number of times medication was not used during each efficacy evaluation period;

[0062] Within each efficacy evaluation period, for each target indicator, the self-reported improvement change was obtained based on the difference between adjacent parameters in the parameter curve. The self-reported improvement change was weighted using the medication influence weight to obtain the self-reported improvement parameter.

[0063] During each efficacy evaluation period, the improvement parameters are obtained based on the change in each medical examination indicator. The confidence weight of efficacy is obtained based on the difference between the improvement parameters of each target indicator and the self-tested improvement parameters.

[0064] In a preferred embodiment of the present invention, considering that the more times the medication was not taken relative to the number of times the medication was taken, the more serious the patient's missed medication or interrupted medication, and the greater the impact on the efficacy, the ratio of the number of times the medication was not taken to the number of times the medication was taken is negatively correlated and normalized, and the normalized value is used as the weight of the impact of medication.

[0065] It should be noted that the target indicators include those positively correlated with lung function, such as blood oxygen saturation. An increase in blood oxygen saturation indicates an improvement in the patient's lung function. The target indicators also include those negatively correlated with lung function, such as heart rate and respiratory rate. A stable or appropriately reduced heart rate and respiratory rate indirectly indicate the relief of the patient's dyspnea and the improvement of lung function.

[0066] Therefore, as an example, in each efficacy evaluation period, the number of times no medication was used is first used as the numerator, the number of times medication was used is used as the denominator, and the ratio of the fractions is used as the x in the exponential function exp(-x) with the natural constant e as the base is negatively normalized to obtain the weight of the effect of medication.

[0067] Then, in the parameter curve of each target indicator, the difference between each parameter and the adjacent previous parameter is taken as the parameter increment, where the parameter increment may be positive, negative or zero; for target indicators that are positively correlated with lung function, the mean of all parameter increments is taken as the self-tested improvement change; for target indicators that are negatively correlated with lung function, the inverse of the mean of all parameter increments is taken as the self-tested improvement change; then, the medication influence weight is multiplied by the self-tested improvement change to obtain the self-tested improvement parameter for each target indicator;

[0068] Similarly, the change in each medical examination indicator may be positive, negative, or zero. For medical examination indicators that are positively correlated with lung function, the change in the indicator is directly used as a parameter for improvement. For medical examination indicators that are negatively correlated with lung function, the inverse of the change in the indicator is used as a parameter for improvement.

[0069] Finally, within each efficacy evaluation period, the absolute value of the ratio of the improvement parameter at the time of medical visit to the self-tested improvement parameter for each target indicator, minus 1, is used as x in the exponential function exp(-x) with the natural constant e as the base, and negatively normalized to obtain the efficacy confidence weight; so that the closer the improvement parameter at the time of medical visit is to the self-tested improvement parameter, the greater the efficacy confidence weight.

[0070] Step S202: During each efficacy evaluation period, based on the single dose and the change in each medical examination indicator, the initial efficacy parameters for each medical examination indicator are obtained. The corresponding initial efficacy parameters are weighted using the efficacy confidence weight of each medical examination indicator, and the weighted result is used as the efficacy parameter.

[0071] Considering that the smaller the single dose of medication in each efficacy evaluation period, and the larger the improvement parameter at the time of consultation, it can be said that the patient is more sensitive to the drugs in the medication regimen, and a small amount of medication can achieve a good effect; the change in each indicator at the time of consultation can be used to evaluate the improvement parameter at the time of consultation; and considering that the efficacy confidence weight reflects the confidence of the improvement parameter at the time of consultation to a certain extent, it can be said that it reflects the accuracy of the efficacy evaluation based on its analysis.

[0072] Based on this, in one embodiment of the present invention, the initial efficacy parameters of each medical examination indicator are first obtained during each efficacy evaluation period, and then the efficacy confidence weight of each medical examination indicator is multiplied by the corresponding initial efficacy parameter to obtain the efficacy parameters under each medical examination indicator.

[0073] In a preferred embodiment of the present invention, the method for obtaining the initial therapeutic parameters includes:

[0074] The negative correlation normalized value of the single dose within each efficacy evaluation period is used as the medication sensitivity weight. Under each medical examination indicator, the medication sensitivity weight is used to weight the corresponding medical improvement parameter, and the weighted result is used as the initial efficacy parameter.

[0075] As an example, the single dose of medication in each efficacy evaluation period is reciprocally normalized with negative correlation to obtain the medication sensitivity weight. Then, the medication sensitivity weight is multiplied by the corresponding improvement parameter to obtain the initial efficacy parameter. It should be noted that the single dose set in the medication regimen cannot be 0, so the reciprocal calculation is meaningful.

[0076] The efficacy assessment module 103 is used to determine the reference time period of the current moment from all efficacy assessment time periods based on the similarity characteristics of single medication dosage; and to determine the future follow-up time of the current moment and assess the efficacy at the future follow-up time based on the fluctuation characteristics of the efficacy parameters of all medical examination indicators and the parameter curves of all daily self-test indicators within all reference time periods for each duration.

[0077] Considering that similar medication dosages usually reflect similar medication regimens among patients, and indirectly reflect similar lung function status, the recovery and efficacy of patients under similar conditions and medication regimens should also be similar, and the follow-up visit intervals may also be similar. Therefore, historical efficacy evaluation periods with similar medication dosages at the current moment can provide some reference information for evaluating the expected follow-up visit interval at the current moment. Based on this, the embodiments of the present invention first determine the reference period at the current moment from all efficacy evaluation periods according to the similarity characteristics of single medication dosages.

[0078] Preferably, in one embodiment of the present invention, considering that clustering can group similar data into a cluster, the method for obtaining the reference time period includes:

[0079] The current single dose of medication for the patient at the current moment is taken as the current dose. The single doses and current doses within each efficacy evaluation period are clustered. All efficacy evaluation periods corresponding to all single doses other than the current dose within the cluster containing the current dose are taken as the reference period for the current moment.

[0080] As an example, firstly, the single dose and current dose of all efficacy assessment periods are used as cluster objects. The optimal K value is obtained using the elbow method. Then, based on the optimal K value and the K-means clustering algorithm, all cluster objects are clustered. Then, the cluster containing the current dose is selected. The single dose in this cluster is similar to the current dose, so all reference periods at the current moment can be determined.

[0081] It should be noted that the elbow method and K-means clustering algorithm are existing technologies and will not be elaborated further.

[0082] Considering that follow-up visits also need to assess whether the patient has achieved the expected therapeutic effect under the current medication regimen, so as to help doctors evaluate the stability of the therapeutic effect during follow-up visits, adjust the medication regimen in a timely manner, and improve the long-term management effect of chronic obstructive pulmonary disease; therefore, after obtaining all reference time periods, the efficacy of each follow-up reference interval can be evaluated based on the efficacy reference information provided by all reference time periods under each duration, i.e., each follow-up reference interval. Then, the future reference time can be determined based on the follow-up reference interval corresponding to the best expected therapeutic effect.

[0083] Furthermore, considering that patients need to take medication regularly during each reference period, the parameter curves of daily self-test indicators will fluctuate after medication; at the same time, patients' lifestyle habits may also lead to improvement or deterioration of lung function to some extent, which will also cause fluctuations in the parameter curves; the fluctuations in the parameter curves reflect the sensitivity of the corresponding daily self-test indicators to external influences during the reference period. The greater the sensitivity, the greater its impact on lung function, and the higher the attention should be paid to it when evaluating the efficacy.

[0084] Based on this, the embodiments of the present invention will determine the future follow-up time at the current moment and evaluate the efficacy at the future follow-up time by taking into account the efficacy parameters of all medical examination indicators and the fluctuation characteristics of the parameter curves of all daily self-test indicators within all reference time periods under each duration.

[0085] Preferably, in one embodiment of the present invention, the method for obtaining the time of future follow-up visits includes:

[0086] Please see Figure 3 The diagram illustrates a flowchart of a method for obtaining future follow-up appointment times according to an embodiment of the present invention, specifically including:

[0087] Step S301: Within each reference time period, obtain the attention weight of each target indicator based on the fluctuation characteristics of the parameter curve of each target indicator, and set the attention weight of the remaining medical examination indicators other than the target indicators as preset positive parameters.

[0088] Given that the more drastic the fluctuations in the parameter curve, the greater the attention should be paid to the corresponding daily self-test indicators; and considering that the indicators for medical examinations also include other indicators besides the daily self-test indicators for which parameter curves cannot be obtained, they need to be discussed separately.

[0089] In one embodiment of the present invention, the daily self-test indicators in the medical examination test indicators are first used as target indicators, and the attention weight of each target indicator is further obtained; then, considering that the other medical examination test indicators besides the target indicators are tested during medical visits, and that they are also of great significance for assessing the patient's lung function, their attention weights are artificially set as preset positive parameters.

[0090] In a preferred embodiment of the present invention, considering that variance can reflect the fluctuation characteristics of data, the normalized value of the variance of the parameter curve of each target indicator is specifically used as the attention weight of each target indicator; wherein, the normalization method used is linear normalization, which is already existing technology and will not be described in detail.

[0091] Since the target indicator's weight ranges from 0 to 1, the preset positive parameter is set to 1. Implementers can also define their own preset positive parameter, such as any value between 0.5 and 1, but it should not be too small.

[0092] Step S302: Classify all reference time periods according to duration. In each category corresponding to each duration, obtain the expected efficacy value for each duration based on the attention weight and efficacy parameters of all medical examination indicators in all reference time periods.

[0093] To analyze the efficacy of each duration, i.e., each follow-up visit interval, and to determine the reference interval for the best expected efficacy at the current moment, thereby determining the future follow-up visit time, one embodiment of the present invention first classifies all reference time periods according to duration. That is, it first counts the durations corresponding to all reference time periods, and groups reference time periods with the same duration as a category, thereby obtaining the expected efficacy value under each duration.

[0094] The expected efficacy value reflects the comprehensive efficacy assessment results in the historical efficacy assessment phase at each duration, preparing for the subsequent determination of the optimal efficacy corresponding duration, i.e., the follow-up visit interval.

[0095] In a preferred embodiment of the present invention, the method for obtaining the expected therapeutic effect value includes:

[0096] Under each type of duration, the corresponding efficacy parameters are weighted by the attention weight of each medical examination and testing indicator within each reference time period, and the weighted sum of all reference time periods is used as the expected efficacy sub-parameter under each medical examination and testing indicator.

[0097] The sum of the expected efficacy sub-parameters for all medical examination indicators under each duration is used as the expected efficacy value for each duration.

[0098] As an example, taking any duration category, the formula for calculating the expected therapeutic value is:

[0099] Where f is the expected therapeutic effect value for that duration; t is the sequence number of the reference time period; T is the total number of reference time periods; i is the sequence number of the medical examination indicator; and N is the total number of medical examination indicators. The focus weight of the i-th medical visit testing indicator within the t-th reference time period; The efficacy parameters of the i-th medical examination indicator within the t-th reference time period; Let be the expected efficacy sub-parameter under the i-th medical examination indicator.

[0100] Step S303: The duration corresponding to the maximum expected efficacy value is taken as the expected efficacy assessment duration at the current moment, and the future follow-up visit time is determined using the expected efficacy assessment duration and the current moment.

[0101] As an example, the expected efficacy assessment duration reflects the optimal follow-up interval at the current stage. After obtaining the expected efficacy assessment duration at the current moment, the previous adjacent visit time is taken as the starting point of the current efficacy assessment period. Then, the endpoint, i.e. the future follow-up visit time, is determined by combining the expected efficacy assessment duration.

[0102] In one embodiment of the present invention, after obtaining the future follow-up appointment time from the current moment, the smart bracelet will remind the patient to have a follow-up appointment when the future follow-up appointment time arrives to assess the efficacy during the current efficacy assessment period. During the follow-up appointment, relevant medical staff will guide the patient to fill out the Chronic Obstructive Pulmonary Disease Assessment Test (CAT) form according to their own situation, and finally obtain the CAT form score. The higher the score, the more the patient's lung function or respiratory function is declining, and the worse the efficacy is. At the same time, relevant medical tests will be conducted for the patient, and the efficacy will be assessed in combination with the test results to assist relevant medical staff in adjusting the medication plan. Through continuous adjustment of the medication plan and real-time monitoring and analysis, long-term dynamic efficacy assessment and management of chronic obstructive pulmonary disease can be carried out to improve the patient's quality of life.

[0103] In summary, this invention first acquires monitoring data from patients during each efficacy evaluation period since they began taking medication. Then, within each efficacy evaluation period, it combines the number of times medication was not used and the single dose to obtain efficacy parameters for each medical examination indicator. Furthermore, it determines the reference time period for the current moment based on the single dose, and based on the monitoring data within all reference time periods for each duration, it determines the future follow-up appointment time for the current moment and evaluates the efficacy. This invention compares two types of data obtained from daily monitoring and medical examinations, and accurately assesses efficacy in conjunction with the patient's medication history. Then, based on efficacy evaluation periods with similar medication dosages in the long-term management of chronic obstructive pulmonary disease (COPD), it evaluates the efficacy under each duration, i.e., the follow-up interval, to determine the optimal future follow-up appointment time, i.e., to determine the optimal management time period for the current stage. This allows patients to have reasonable follow-up appointments to adjust their medication regimen, thereby improving the dynamic evaluation effect of patient efficacy.

[0104] It should be noted that the order of the above embodiments of the present invention is merely for descriptive purposes and does not represent the superiority or inferiority of the embodiments. The processes depicted in the accompanying drawings do not necessarily require a specific or sequential order to achieve the desired result. In some embodiments, multitasking and parallel processing are also possible or may be advantageous.

[0105] The various embodiments in this specification are described in a progressive manner. The same or similar parts between the various embodiments can be referred to each other. Each embodiment focuses on describing the differences from other embodiments.

Claims

1. A dynamic evaluation system for the treatment efficacy of chronic obstructive pulmonary disease, characterized in that, The system includes: Data acquisition module: used to acquire the number of times the patient did not take medication, the single dose, the parameter curve of each daily self-test indicator, and the change in each medical examination indicator during each efficacy evaluation period since the patient started taking medication; among which the medical examination indicators include the daily self-test indicators; Data analysis module: used to obtain efficacy parameters for each medical visit indicator based on the changing trend of the parameter curves of each daily self-test indicator and the change in each medical visit test indicator during each efficacy evaluation period, combined with the number of times medication was not used and the single dose of medication; the method for obtaining the efficacy parameters includes: The daily self-test indicators in the medical examination and testing indicators are used as target indicators, and the efficacy confidence weights of the other medical examination and testing indicators are set to a constant of 1. During each efficacy evaluation period, the efficacy confidence weights of each target indicator are obtained based on the change of each target indicator and the difference between adjacent parameters in the parameter curve, combined with the number of times medication was not used. During each efficacy evaluation period, based on the single dose and the change in each medical examination indicator, the initial efficacy parameters for each medical examination indicator are obtained. The initial efficacy parameters are then weighted using the efficacy confidence weights for each medical examination indicator, and the weighted results are used as efficacy parameters. The efficacy assessment module is used to determine the reference time period for the current moment from all efficacy assessment time periods based on the similarity characteristics of the single dose; and to determine the future follow-up time for the current moment based on the fluctuation characteristics of the efficacy parameters under all medical examination indicators and the parameter curves of all daily self-test indicators within all reference time periods for each duration, and to assess the efficacy at the future follow-up time.

2. The dynamic evaluation system for the treatment efficacy of chronic obstructive pulmonary disease according to claim 1, characterized in that, The efficacy evaluation period is the time between adjacent visits.

3. The dynamic evaluation system for the treatment efficacy of chronic obstructive pulmonary disease according to claim 1, characterized in that, The methods for obtaining the efficacy confidence weights of the target indicators include: The influence weight of medication use is obtained based on the number of times medication was not used during each efficacy evaluation period; During each efficacy evaluation period, for each target indicator, the self-tested improvement change is obtained based on the difference between adjacent parameters in the parameter curve. The self-tested improvement change is then weighted using the medication influence weight to obtain the self-tested improvement parameter. During each efficacy evaluation period, the improvement parameters are obtained based on the change in each medical visit test indicator, and the efficacy confidence weight is obtained based on the difference between the improvement parameters of each target indicator and the self-tested improvement parameters.

4. The dynamic evaluation system for the treatment efficacy of chronic obstructive pulmonary disease according to claim 3, characterized in that, The method for obtaining the weight of the medication effect includes: The ratio of the number of times no medication was used to the number of times medication was used was negatively correlated and normalized, and the normalized value was used as the weight of the impact of medication.

5. The dynamic evaluation system for the treatment efficacy of chronic obstructive pulmonary disease according to claim 3, characterized in that, The method for obtaining the initial therapeutic parameters includes: The negative correlation normalized value of the single dose within each efficacy evaluation period is used as the medication sensitivity weight. Under each medical examination indicator, the medication sensitivity weight is used to weight the corresponding medical improvement parameter, and the weighted result is used as the initial efficacy parameter.

6. The dynamic evaluation system for the treatment efficacy of chronic obstructive pulmonary disease according to claim 1, characterized in that, The method for obtaining the reference time period includes: The patient's single dose at the current moment is taken as the current dose. The single dose and the current dose in each efficacy evaluation period are clustered. All efficacy evaluation periods corresponding to all single doses other than the current dose in the cluster containing the current dose are taken as the reference period for the current moment.

7. The dynamic evaluation system for the treatment efficacy of chronic obstructive pulmonary disease according to claim 1, characterized in that, The methods for obtaining the future follow-up visit time include: Within each reference period, the attention weight of each target indicator is obtained based on the fluctuation characteristics of the parameter curve of each target indicator, and the attention weight of the other medical examination and testing indicators other than the target indicators is set as a preset positive parameter. All the reference time periods are classified according to their duration. In each category corresponding to each duration, the expected efficacy value for each duration is obtained based on the attention weight of all medical examination indicators and the efficacy parameters within all reference time periods. The duration corresponding to the maximum value of the expected therapeutic effect is taken as the expected therapeutic effect assessment duration at the current moment, and the future follow-up visit time is determined using the expected therapeutic effect assessment duration and the current moment.

8. The dynamic evaluation system for the treatment efficacy of chronic obstructive pulmonary disease according to claim 7, characterized in that, The methods for obtaining the attention weight of the target indicator include: The normalized value of the variance of the parameter curve for each target indicator is used as the attention weight for each target indicator.

9. The dynamic evaluation system for the treatment efficacy of chronic obstructive pulmonary disease according to claim 7, characterized in that, The method for obtaining the expected therapeutic value includes: Under each type of duration, the corresponding efficacy parameter is weighted using the attention weight of each medical examination and testing indicator within each reference time period, and the weighted summation result corresponding to all reference time periods is used as the expected efficacy sub-parameter under each medical examination and testing indicator. The sum of the expected efficacy sub-parameters for all medical examination indicators under each duration is taken as the expected efficacy value for each duration.

Images